Looking at the wider impact of the Sanofi-Genzyme deal
This article was originally published in Scrip
After nearly nine months of informal and formal discussion, Sanofi-Aventis finally succeeded in persuading Genzyme's board that the company and its stakeholders would be better off as part of the French pharma giant. As the empty champagne bottles are collected for recycling, the conclusion of the negotiations throws up a whole new raft of questions related to the future of the biotech Industry.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.